2021
Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL
Beckwith H, Schwab R, Yau C, Stringer-Reasor E, Wei S, Chien A, Albain K, Kalinsky K, Wallace A, Elias A, Yee D, Clark A, Boughey J, Han H, Nanda R, Isaacs C, Mitri Z, Lang J, Thomas A, Sanft T, DeMichele A, Perlmutter J, Rugo H, Hylton N, Symmans W, Melisko M, van't Veer L, Wilson A, Asare S, Sanil A, Berry D, Esserman L. Abstract PD1-10: Evaluation of SGN-LIV1a followed by AC in high-risk HER2 negative stage II/III breast cancer: Results from the I-SPY 2 TRIAL. Cancer Research 2021, 81: pd1-10-pd1-10. DOI: 10.1158/1538-7445.sabcs20-pd1-10.Peer-Reviewed Original ResearchStage II/III breast cancerWeekly x 4I-SPY 2 TRIALI-SPY 2PCR rateBreast cancerI-SPYPeripheral neuropathyHigh-risk stage II/III breast cancerTumor samplesRates of peripheral neuropathyControl armEvaluate novel agentsPathological complete responsePhase 2 trialTreatment of angiosarcomaModerate to high expressionSide effect profileTime of surgeryBayesian predictive probability of successBreast tumor samplesAntibody drug conjugatesHR-HER2Complete responseNeoadjuvant therapy
2017
Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer.
Foldi J, Mougalian S, Silber A, Lannin D, Killelea B, Chagpar A, Horowitz N, Frederick C, Rispoli L, Abu-Khalaf M, Sabbath K, Sanft T, Fischbach N, Brandt D, Hofstatter E, DiGiovanna M, Pusztai L. Pathologic complete response (pCR) rates after neoadjuvant pertuzumab (P) and trastuzumab (H) administered concomitantly with weekly paclitaxel (T) and 5-fluorouracil/epirubicin/cyclophosphamide (FEC) chemotherapy for clinical stage I-III HER2-positive breast cancer. Journal Of Clinical Oncology 2017, 35: 577-577. DOI: 10.1200/jco.2017.35.15_suppl.577.Peer-Reviewed Original ResearchPathologic complete response rateHER2-positive breast cancerDual HER2 blockadeComplete response ratePCR rateEstrogen receptorHER2 blockadeBreast cancerStage IResponse rateGrade 3/4 adverse eventsSymptomatic congestive heart failureClinical stage ICompletion of chemotherapyPhase II studyTaxane-based chemotherapyCongestive heart failureEfficacy of anthracyclinesPositive breast cancerNormal cardiac functionEntire treatment durationER cohortER- cancersNeoadjuvant pertuzumabWeekly paclitaxel